1st Biosimilars Act Ruling May Limit Patent Challenges

Law360, New York (November 13, 2013, 7:24 PM EST) -- The ability of biosimilars makers to make early challenges to biologic drug patents may be curtailed by a Tuesday ruling throwing out Sandoz Inc.'s suit to invalidate patents for Amgen Inc.'s biologic arthritis drug Enbrel, the first time a judge has interpreted the litigation provisions of the Biosimilars Act.

Sandoz, which is working on a biosimilar version of Enbrel but has not yet sought government approval, filed suit in June seeking declaratory judgment that its version would not infringe and that the patents are invalid....
To view the full article, register now.